In this study, we investigated whether the PKM2 activator, TEPP-46, and the LDHA inhibitor, FX-11, can be effectively combined to inhibit in vitro and in vivo tumor growth in preclinical models of pancreatic cancer. This evidence concerns the gene SPMIP8 and neoplasm.